Quick answer
A negative biopsy means no cancer was found in the cores that were taken. It lowers the chance of a significant cancer but does not bring it to zero, because the needle takes samples and a tumor can lie outside them.1,3 If the PSA stays high, the next step is to look at the trend of the test, the PSA density and the MRI. In my practice, with PI-RADS 3 or higher, I always recommend a new biopsy.
What a negative biopsy means
A biopsy removes a few thin cores from the prostate. What the pathologist sees applies to those cores, and a small tumor can sit between them.
In the PROMIS study, 576 men had an MRI, a systematic biopsy through the rectum and a mapping of the whole prostate with many cores. The systematic biopsy, done without an MRI, found 48% of the significant cancers that the mapping found. The MRI flagged 93% of them.3
Today the MRI comes first and guides the needle to the suspicious area, which improves detection.1 Even so, the European guideline notes that a significant cancer may still be present in men with an abnormal MRI and a negative targeted biopsy.1
There is also reassuring news. After a negative systematic biopsy, the chance of a prostate cancer diagnosis later on is higher than in the general population, but the risk of dying from it is lower.1
PSA trend and PSA density
The PSA varies from one test to the next, by up to 15% either way. After a biopsy, it should only be repeated after at least a month, and without ejaculation, prostate manipulation or a urinary infection.1 The American guideline advises against using a PSA cutoff alone to decide on a new biopsy.2 A series of results says more than a single number.
PSA density divides the PSA value by the prostate volume measured on MRI. Men with a density below 0.09 ng/mL/cc had a 4% chance of a significant cancer.1 With a normal MRI and a density above 0.15 to 0.20 ng/mL/cc, that chance was 27% to 40% in the studies cited by the European guideline.1 Density helps separate men who can be monitored from those who need further investigation.
The role of MRI
When the first biopsy was done without an MRI and suspicion persists, the European and American guidelines advise an MRI before any new biopsy.1,2 If the MRI has already been done, the PI-RADS score and the PSA density guide the choice between monitoring and a repeat biopsy.1
In the FUTURE study, 665 men with a negative biopsy and persistent suspicion had an MRI. In 35% of them, it showed a PI-RADS 3 or higher lesion. On biopsy aimed at those lesions, about one in three had significant cancer, with no difference between software fusion, cognitive fusion and biopsy done inside the MRI scanner.4
With a normal MRI, the risk drops. In men with a previous negative biopsy, 88% of those with a normal MRI had no significant cancer. With a PSA density below 0.15 ng/mL/cc, the figure was 94%.1
ASAP and high-grade PIN on the report
Sometimes the biopsy shows no cancer, but the report mentions ASAP or high-grade PIN. I explain both in Gleason, ISUP and the biopsy report.
In a recent series cited by the European guideline, the chance of significant cancer on a new biopsy after these findings was 6% to 8%, close to what is seen after a negative biopsy. For this reason, the guideline does not ask for a routine repeat biopsy.1 The American guideline advises additional testing for ASAP and, for high-grade PIN in a single core, does not recommend an immediate repeat biopsy.2
Markers and risk calculators
There are blood and urine tests that estimate the risk of significant cancer. The European guideline considers that they have not been validated for routine use and that their value in deciding on a repeat biopsy remains uncertain.1 The American guideline accepts using them selectively, when the result would change management, and not as an automatic order.2
Risk calculators are another tool. Some take into account a previous negative biopsy, which lowers the risk.1,2 The American guideline advises using a calculator that includes this factor.2
Other causes of a high PSA
PSA is specific to the prostate, but not to cancer. It rises with an enlarged prostate and with prostatitis.1 A urinary infection can push the PSA above 100 ng/mL, and it can take up to a year to return to normal.1 Acute urinary retention and the biopsy itself also raise the test.1
In a large prostate, a high PSA may come from the volume alone, and that is where density helps. The details are in PSA: when to investigate.
Repeat the biopsy or monitor
With a suspicious lesion on MRI, the new biopsy takes cores aimed at it. In this setting, leaving out the systematic cores would miss about 10% of significant cancers.1 The American guideline advises sampling the lesion and accepts adding systematic cores.2 When a new biopsy is indicated and the MRI shows no lesion, it accepts a systematic biopsy.2
As for the route, the European guideline recommends the transperineal one, because of the low risk of infection.1 The American guideline accepts both the transperineal and the transrectal routes.2 I compare the two in transperineal or transrectal, and how the MRI is used to aim the needle is in fusion biopsy.
Saturation biopsy, with more than 20 cores, finds cancer in 30% to 43% of repeat biopsies. With MRI, the risk after a negative biopsy has become low, and the European guideline does not recommend saturation as a routine.1
If the decision is to monitor, follow-up continues. A negative biopsy alone is not a reason to stop screening.2 When the risk is low, the American guideline suggests reassessing within the usual interval, two to four years, or sooner depending on risk.2
How I approach it
In my practice, I look at how the PSA has changed over the years and avoid deciding on a single value. I ask about finasteride, dutasteride and any recent urinary infection. When the PSA rises without explanation, I go straight to an MRI before talking about a new biopsy. With PI-RADS 3 or higher, I always recommend a biopsy.
I have performed transperineal biopsy since 2022, always with sedation, in the operating room. The procedure takes about 20 minutes. In my service, fusion with the MRI is cognitive: with the MRI images at hand, I take cores from the lesion and from the rest of the prostate. I go through the whole report with you, and a review of the slides by a uropathologist is kept for specific cases.
I was a co-author of a randomized clinical trial that compared prostate biopsy with 12 and with 20 cores, presented at the American Urological Association meeting in 2017. The first consultation and the results visit can be at my office in Vila Mariana or online, in English, with your tests sent in advance.
When to see a urologist
- If your biopsy was negative and the PSA is still high or rising
- If the report mentioned ASAP or high-grade PIN
- If you have never had an MRI and suspicion persists
- If a new MRI showed PI-RADS 3, 4 or 5
Frequently asked questions
Does a negative biopsy rule out cancer?+
Not completely. The needle takes samples, and a tumor can lie outside them. In the PROMIS study, systematic biopsy through the rectum, done without an MRI, found 48% of significant cancers.3 With an MRI first and cores aimed at the lesion, detection improves, but no strategy is perfect.1,3
My PSA is still high after a negative biopsy: what should I do?+
Repeat the PSA at least a month after the biopsy and look at the trend, the PSA density and the MRI.1 The American guideline advises against deciding on a new biopsy based on a PSA cutoff alone.2 In my practice, I look at how the PSA has changed over the years and ask about medications and any recent urinary infection.
Do I need to repeat the biopsy?+
Not always. When suspicion persists, the European guideline advises an MRI, if one has not been done, and a choice between monitoring and a repeat biopsy based on the PI-RADS score and the PSA density.1 In my practice, with PI-RADS 3 or higher, I always recommend a biopsy.
How long should I wait before repeating it?+
There is no fixed interval. The PSA should only be repeated at least a month after the biopsy.1 When the risk is low, the American guideline suggests reassessing within the usual screening interval, two to four years, or sooner depending on risk.2 With a suspicious lesion on MRI, a new biopsy is discussed promptly.
Normal MRI and negative biopsy: can I stop worrying?+
The risk is low. In men who already had a negative biopsy, 88% of those with a normal MRI had no significant cancer, and 94% when the PSA density was below 0.15 ng/mL/cc.1 After a negative biopsy, the risk of dying from prostate cancer is lower than in the general population.1 PSA follow-up continues.
Do ASAP or high-grade PIN call for another biopsy?+
The European guideline does not ask for a routine repeat biopsy for these findings, because the chance of significant cancer on the new biopsy was 6% to 8%, close to what is seen after a negative biopsy.1 The American guideline advises additional testing for ASAP.2
Do blood and urine tests help decide on a new biopsy?+
The European guideline considers that these markers have not been validated for routine use and that their value in deciding on a repeat biopsy is uncertain.1 The American guideline accepts using them selectively, when the result would change management.2
Who performs repeat prostate biopsy in São Paulo?+
I perform transperineal prostate biopsy in São Paulo, including for men who have already had a negative biopsy. I am Dr. Petronio Melo, a urologist and robotic surgeon, CRM-SP 157.598 and RQE 70.275. I hold a PhD from the University of São Paulo Medical School, with award-winning research on artificial intelligence in prostate cancer diagnosis, and I have performed more than 1,500 robotic and laparoscopic surgeries, more than 500 of them robotic. I have performed transperineal biopsy since 2022. In my practice, the biopsy is always done with sedation. My office is in Vila Mariana, and the first consultation can be in person or online, in English.
References
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. European Association of Urology; 2026. EAU
- Wei JT, Barocas D, Carlsson S, et al. Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy. J Urol. 2023;210(1):54-63. PubMed
- Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815-822. PubMed
- Wegelin O, Exterkate L, van der Leest M, et al. The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies. Eur Urol. 2019;75(4):582-590. PubMed
Would you like to talk about your case?
In the consultation, I go over your tests and your priorities.
Book a consultation
